@article{04680f0c70ed467c840b1d939df6603e,
title = "Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test",
author = "Taro Kishi and Hiroshi Nakamura and Nakao Iwata",
note = "Funding Information: Mr Nakamura is full‐time employee of Sumitomo Pharma Co., Ltd. All other authors have declared that there are no conflicts of interest relating to the subject of this study. No grant support or other sources of funding were used to conduct this study or prepare this article. Interests for the past 3 years are as follows: Dr Kishi received speakers{\textquoteright} honoraria from Sumitomo, Otsuka, Eisai, Janssen, Takeda, Kyowa, Meiji, Eli Lilly, and MSD; as well as research grants from Eisai, the Japanese Ministry of Health, Labour and Welfare (H29‐Seishin‐Ippan‐001, 19GC1012), Grant‐in‐Aid for Scientific Research (C), and Fujita Health University School of Medicine. Professor Iwata received speakers{\textquoteright} honoraria from Sumitomo, Eli Lilly, Janssen, Meiji, Otsuka, and Takeda, as well as research grants from Sumitomo, Eisai, Otsuka, and Takeda; along with research grants from Daiichi Sankyo, Takeda, Sumitomo, Eisai, Tanabe‐Mitsubishi, and Otsuka. ",
year = "2022",
month = aug,
doi = "10.1111/pcn.13377",
language = "English",
volume = "76",
pages = "401--402",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "8",
}
SDG 3 Good Health and Well-being